Clip for the initial time.The video depicts, as described aboveClip for the initial time.The video depic

The European society of cardiology: developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803?69. Rose GA, Blackburn H: Cardiovascular survey methods. Geneva: World Health Organisation; 1982. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al: Recommendations for chamber quantification: a report from the American society

Programme): an international survey. Lancet 2002, 360:1631?639. Rutten FH, Grobbee DE, Hoes AW: Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003, 5:337?44. Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galanti G, et al: Prognostic value of 6-minute walk corridor test in patients

Rt TC, Marino PN, Oh JK, Smiseth OA, et al: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22:107?33. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111?17. Rutten FH, Walma EP, Kruizinga GI, Ba

Rt TC, Marino PN, Oh JK, Smiseth OA, et al: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22:107?33. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111?17. Rutten FH, Walma EP, Kruizinga GI, Ba

Software licensing audit

Cosine6 provides technology due diligence services and research for venture capital and private equity groups.

COSINE6's Technology Audit relies on the following key information in order to gather a holistic account of a company's technology assets:

Samples of all of the products of the company and all supporting documentation and past versions

Details about products currently being developed

Detailed technical architecture of all the products developed or being developed

Copies of all agreements which convey, assign or otherwise transfer any past, present

Es would most likely not have been affected. The measures of immune activation were not assessed at enrollment into the study cohort, and we therefore cannot make temporal inferences of a causal nature nor could we control for them in the multivariable Cox models. We used prevalence rate ratios (PRRs) to estimate the associations of interest as risk was our parameter of interest. We chose PRRs as

Espite successful HCV eradication. Other complications such as development of carcinoma may be more readily amenable to more rapid risk reduction with antiviral therapy. Further studies with long periods of follow-up will be needed to address these questions. Our study has several limitations. Not all patients had measures of immune activation documented in their study records and were therefore e